Vildagliptin For Type II Diabetes Can Be Combined With All Other Diabetes Drugs
This article was originally published in PharmAsia News
Executive Summary
Partial changes to the efficacy and indication of Novartis Pharmaceuticals’ DPP-4 inhibitor drug Equa (vildagliptin) have been approved, the company announced on Feb. 28.